Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Melanoma 3Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1

Interventions

Cyclophosphamide 32Etoposide 18romidepsin 17fludarabine 17Vincristine 17Doxorubicin 16Rituximab 14Prednisone 14Melphalan 14Gemcitabine 13Brentuximab Vedotin 13Lenalidomide 12Peripheral Blood Stem Cell Transplantation 11Cytarabine 11Whole-Body Irradiation 10Biopsy 1010-propargyl-10-deazaaminopterin 10pembrolizumab 9fludarabine phosphate 9Specimen Handling 9Busulfan 9Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Depsipeptides 8Carmustine 8Bortezomib 8duvelisib 7Vorinostat 7Methotrexate 7Magnetic Resonance Spectroscopy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × Interleukin-15 × Clear all
NCT03905135 2022-09-13

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
8 enrolled 18 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡